US 9,809,559 B2
(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
Brandon H. Brown, Burlingame, CA (US); Ernest A. Carra, Foster City, CA (US); Jeffrey N. Hemenway, San Mateo, CA (US); Henry Morrison, Dublin, CA (US); Troy Reynolds, San Francisco, CA (US); Bing Shi, Redwood City, CA (US); Dimitrios Stefanidis, Mountain View, CA (US); Fang Wang, Foster City, CA (US); Matthew Robert Warr, Madison, CT (US); James Andrew Whitney, Guilford, CT (US); and Yan Xin, San Carlos, CA (US)
Assigned to GILEAD SCIENCES, INC., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Aug. 8, 2016, as Appl. No. 15/231,411.
Application 15/231,411 is a continuation of application No. 14/736,690, filed on Jun. 11, 2015, granted, now 9,469,613.
Claims priority of provisional application 62/011,315, filed on Jun. 12, 2014.
Prior Publication US 2016/0347719 A1, Dec. 1, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/535 (2006.01); A61K 31/5377 (2006.01); C07D 239/42 (2006.01); C07D 265/30 (2006.01)
CPC C07D 239/42 (2013.01) [A61K 31/535 (2013.01); A61K 31/5377 (2013.01); C07D 265/30 (2013.01); C07B 2200/13 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A method of treating myelofibrosis or polycythemia vera comprising administering to a subject in need thereof a compound selected from the group consisting of:
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate Form II;
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form I; and
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous Form III.